Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

1. Coles, A.J.
2. Jones, J.L.
3. Vermersch, P.
4. Traboulsee, A.
5. Bass, A.D.
6. Boster, A.
7. Chan, A.
8. Comi, G.
9. Fernández, Ó.
10. Giovannoni, G.
11. Kubala Havrdova, E.
12. LaGanke, C.
13. Montalban, X.
14. Oreja-Guevara, C.
15. Piehl, F.
16. Wiendl, H.
17. Ziemssen, T.